OBJECTIVE:To optimise point application therapy for the treatment of asthma.METHODS:A total of 456 patients with asthma were randomly divided into treatment groups 1,2,and 3,with 152 patients each.The Dazhui(GV14),Fei...OBJECTIVE:To optimise point application therapy for the treatment of asthma.METHODS:A total of 456 patients with asthma were randomly divided into treatment groups 1,2,and 3,with 152 patients each.The Dazhui(GV14),Feishu(BL13),Xinshu(BL15),Geshu(BL17),Pishu(BL20),Shenshu(BL23),and Guanyuan(CV4)acupoints were selected for treatment groups 1 and 2,with 2 and 4 h of application,respectively.The Feishu(BL13),Xinshu(BL15),and Geshu(BL17)acupoints were selected in group 3,with 2 h of application.All patients underwent application of the“prevention of disease”plaster during the dog days of summer(approximately July and August each year)between 2015 and 2019.RESULTS:The analysis showed that the numbers of asthma attacks and total serum immunoglobulin E(IgE)levels of the three groups after treatment were significantly lower than those before treatment.In addition,the reductions in treatment groups 1 and 2 were more significant than those in group 3.The total treatment efficacy rates and post-treatment quality of life scores of the patients in treatment groups 1 and 2 were significantly higher than those in group 3.CONCLUSIONS:Point application therapy can effectively improve the clinical symptoms of patients with asthma,reduce the number of attacks,improve the quality of life,and decrease the total serum IgE level.The choice of acupuncture points,but not the length of the application time,influenced the therapeutic effect of point application therapy in asthma.展开更多
OBJECTIVE:To evaluate the efficacy and safety of stimulating acupoints in subjects with childhood cough variant asthma(CVA).METHODS:A Meta-analysis of randomized controlled trials(RCTs) about the comparison between ac...OBJECTIVE:To evaluate the efficacy and safety of stimulating acupoints in subjects with childhood cough variant asthma(CVA).METHODS:A Meta-analysis of randomized controlled trials(RCTs) about the comparison between acupoint sticking therapy and non-acupoint sticking therapy for childhood CVA was conducted.The trials' quality and risk bias were assessed using the Cochrane Handbook tool.Odds ratio(OR) or risk ratio(RR) with 95% confidence intervals(CIs),mean differences(MDs) or standardized mean differences(SMDs) of a random-effects model were calculated.Heterogeneity was assessed by P value and I2 statistics.RESULTS:Thirteen studies were included in our review,indicating that the total effective rate of stimulating-acupoint group is better than that of control group [RR 1.19,95% CI(1.13-1.26),P < 0.00001].The recurrence rate in two years [RR 0.31,95%CI(0.19-0.51),P < 0.000 01] and cough duration[MD =-2.42,95% CI(-3.75,-1.09),P = 0.0004]of childhood CVA in stimulating-acupoint group were significantly lower than those in control group.Besides,stimulating acupoints can reduce the level of Ig E [SMD =-0.75,95% CI(-1.21,-0.30),P = 0.001] and EOS [SMD =-0.36,95% CI(-0.92,0.21),P = 0.22].CONCLUSION:Our findings suggest that stimulating acupoints had positive effects on childhood CVA and was relatively safe treatment.However,more RCTs with more useful indicators are warrant to confirm the current findings.展开更多
OBJECTIVE: To use evidence-based medicine to explore the efficacy of acupoint application(AA) for allergic rhinitis(AR) at different time points and its safety. METHODS: We searched 7 databases(Pub Med, Cochrane, Emba...OBJECTIVE: To use evidence-based medicine to explore the efficacy of acupoint application(AA) for allergic rhinitis(AR) at different time points and its safety. METHODS: We searched 7 databases(Pub Med, Cochrane, Embase, China National Knowledge Infrastructure, Wanfang Database, China Science and Technology Journal Database, and China Biology Medicine disc) as well as the international clinical trial registration platform from January 2010 to March 2020 for randomized controlled trials(RCTs) comparing the efficacy of AA versus placebo, Western Medicine or other alternative therapies on AR. Risk of bias was assessed according to the Cochrane handbook, and statistical analysis was performed using Rev Man 5.3. Outcomes included the total effective rate, recurrence rate, total nasal symptom score(TNSS), visual analogue scale(VAS), quality of life measured by the Rhinitis Quality of Life Questionnaire(RQLQ) or Short Form-36(SF-36), adverse events, and biomarkers including immunoglobulin E(Ig E), peripheral blood eosinophil count(EOS), interleukin-4(IL-4), and interferon gamma(INF-γ). RESULTS: Twenty-eight RCTs involving 3282 participants were included. The short-term and long-term efficacy of AA was significantly better than placebo, including better total effective rate [RR: 3.05, 95%CI(1.84, 5.07), after treatment;RR: 9.29, 95%CI(2.57, 33.66), at 6 months], lower recurrence rate [RR: 0.55, 95%CI(0.45, 0.66), at 6 months;RR: 0.65, 95%CI(0.57, 0.74), at 1 year], lower TNSS [MD:-3.09, 95%CI(-3.58,-2.61), after treatment], and lower RQLQ [MD:-14.79, 95%CI(-21.49,-8.10), after treatment;MD:-11.92, 95%CI(-17.40,-6.45), at 4-6 months]. Compared with Western Medicine, AA had better long-term total effective rate [RR: 1.33, 95%CI(1.05, 1.69), at 3 months;RR: 1.49, 95%CI 1.22 to 1.81, at 1 year) and lower recurrence rate [RR: 0.48, 95%CI(0.39, 0.58), at 6 months;RR: 0.45, 95%CI(0.33, 0.60), at 1 year]. AA had better long-term total effective rate versus acupuncture [RR: 2.06, 95% CI(1.28, 3.31), at 1 year] or oral Chinese medicine [RR: 1.21, 95% CI(1.09, 1.34), ≥ 6 months]. Both AA and Western Medicine can reduce serum levels of Ig E, EOS, and IL-4 after treatment. The main adverse event of AA was local skin reaction without systemic side effects. CONCLUSIONS: The short-term(within one month) and long-term(at 3 months, 6 months and 1 year) efficacy of acupoint application on AR was better than that of placebo. The long-term efficacy of acupoint application was superior to that of Western Medicine(at 3 months, 6 months and 1 year), oral Chinese medicine(at more than 6 months) and acupuncture(at 1 year). AA can reduce serum Ig E, EOS, and IL-4 level of AR patients in a short run. Acupoint application is safe, but severe skin reactions can reduce patient compliance.展开更多
基金Supported by Major Science and Technology Special Project of Zhejiang Province:Research and Application of Key Techniques of Point Application Therapy for Treating Winter Diseases and Summer Diseases to Prevent and Treat Respiratory Allergic Diseases(No.2014C03046-2)the Young Scientists of National Natural Science Foundation of China:Study on the Mechanism of Point Application Therapy Regulating Autophagy of Airway Epithelial Cells in the Treatment of Asthma Based on AMPK/mTOR Signal Pathway,(No.82004454)Zhejiang Traditional Chinese Medicine Administration:based on the Theory of"Lung Intestine Axis",a Comparative Study on the Therapeutic Effect of Different Point Application Therapy on Patients with AnaphyLactic Asthma in Remission Stage(No.2021ZQ035)。
文摘OBJECTIVE:To optimise point application therapy for the treatment of asthma.METHODS:A total of 456 patients with asthma were randomly divided into treatment groups 1,2,and 3,with 152 patients each.The Dazhui(GV14),Feishu(BL13),Xinshu(BL15),Geshu(BL17),Pishu(BL20),Shenshu(BL23),and Guanyuan(CV4)acupoints were selected for treatment groups 1 and 2,with 2 and 4 h of application,respectively.The Feishu(BL13),Xinshu(BL15),and Geshu(BL17)acupoints were selected in group 3,with 2 h of application.All patients underwent application of the“prevention of disease”plaster during the dog days of summer(approximately July and August each year)between 2015 and 2019.RESULTS:The analysis showed that the numbers of asthma attacks and total serum immunoglobulin E(IgE)levels of the three groups after treatment were significantly lower than those before treatment.In addition,the reductions in treatment groups 1 and 2 were more significant than those in group 3.The total treatment efficacy rates and post-treatment quality of life scores of the patients in treatment groups 1 and 2 were significantly higher than those in group 3.CONCLUSIONS:Point application therapy can effectively improve the clinical symptoms of patients with asthma,reduce the number of attacks,improve the quality of life,and decrease the total serum IgE level.The choice of acupuncture points,but not the length of the application time,influenced the therapeutic effect of point application therapy in asthma.
基金The key Science and Technology Projects of Zhejiang Province(Research and Application of Key Techniques for Prevention and Treatment of Allergic Diseases of the Respiratory Tract by Summer Treatment of Winter Disease of Acupoint Application,No.2014C03046-2)
文摘OBJECTIVE:To evaluate the efficacy and safety of stimulating acupoints in subjects with childhood cough variant asthma(CVA).METHODS:A Meta-analysis of randomized controlled trials(RCTs) about the comparison between acupoint sticking therapy and non-acupoint sticking therapy for childhood CVA was conducted.The trials' quality and risk bias were assessed using the Cochrane Handbook tool.Odds ratio(OR) or risk ratio(RR) with 95% confidence intervals(CIs),mean differences(MDs) or standardized mean differences(SMDs) of a random-effects model were calculated.Heterogeneity was assessed by P value and I2 statistics.RESULTS:Thirteen studies were included in our review,indicating that the total effective rate of stimulating-acupoint group is better than that of control group [RR 1.19,95% CI(1.13-1.26),P < 0.00001].The recurrence rate in two years [RR 0.31,95%CI(0.19-0.51),P < 0.000 01] and cough duration[MD =-2.42,95% CI(-3.75,-1.09),P = 0.0004]of childhood CVA in stimulating-acupoint group were significantly lower than those in control group.Besides,stimulating acupoints can reduce the level of Ig E [SMD =-0.75,95% CI(-1.21,-0.30),P = 0.001] and EOS [SMD =-0.36,95% CI(-0.92,0.21),P = 0.22].CONCLUSION:Our findings suggest that stimulating acupoints had positive effects on childhood CVA and was relatively safe treatment.However,more RCTs with more useful indicators are warrant to confirm the current findings.
基金Supported by the Key Science and Technology Projects of Zhejiang Province:Research and Application of Key Techniques for Prevention and Treatment of Allergic Diseases of the Respiratory Tract by Summer Treatment of Winter Disease of Acupoint Application (No. 2014C03046-2)。
文摘OBJECTIVE: To use evidence-based medicine to explore the efficacy of acupoint application(AA) for allergic rhinitis(AR) at different time points and its safety. METHODS: We searched 7 databases(Pub Med, Cochrane, Embase, China National Knowledge Infrastructure, Wanfang Database, China Science and Technology Journal Database, and China Biology Medicine disc) as well as the international clinical trial registration platform from January 2010 to March 2020 for randomized controlled trials(RCTs) comparing the efficacy of AA versus placebo, Western Medicine or other alternative therapies on AR. Risk of bias was assessed according to the Cochrane handbook, and statistical analysis was performed using Rev Man 5.3. Outcomes included the total effective rate, recurrence rate, total nasal symptom score(TNSS), visual analogue scale(VAS), quality of life measured by the Rhinitis Quality of Life Questionnaire(RQLQ) or Short Form-36(SF-36), adverse events, and biomarkers including immunoglobulin E(Ig E), peripheral blood eosinophil count(EOS), interleukin-4(IL-4), and interferon gamma(INF-γ). RESULTS: Twenty-eight RCTs involving 3282 participants were included. The short-term and long-term efficacy of AA was significantly better than placebo, including better total effective rate [RR: 3.05, 95%CI(1.84, 5.07), after treatment;RR: 9.29, 95%CI(2.57, 33.66), at 6 months], lower recurrence rate [RR: 0.55, 95%CI(0.45, 0.66), at 6 months;RR: 0.65, 95%CI(0.57, 0.74), at 1 year], lower TNSS [MD:-3.09, 95%CI(-3.58,-2.61), after treatment], and lower RQLQ [MD:-14.79, 95%CI(-21.49,-8.10), after treatment;MD:-11.92, 95%CI(-17.40,-6.45), at 4-6 months]. Compared with Western Medicine, AA had better long-term total effective rate [RR: 1.33, 95%CI(1.05, 1.69), at 3 months;RR: 1.49, 95%CI 1.22 to 1.81, at 1 year) and lower recurrence rate [RR: 0.48, 95%CI(0.39, 0.58), at 6 months;RR: 0.45, 95%CI(0.33, 0.60), at 1 year]. AA had better long-term total effective rate versus acupuncture [RR: 2.06, 95% CI(1.28, 3.31), at 1 year] or oral Chinese medicine [RR: 1.21, 95% CI(1.09, 1.34), ≥ 6 months]. Both AA and Western Medicine can reduce serum levels of Ig E, EOS, and IL-4 after treatment. The main adverse event of AA was local skin reaction without systemic side effects. CONCLUSIONS: The short-term(within one month) and long-term(at 3 months, 6 months and 1 year) efficacy of acupoint application on AR was better than that of placebo. The long-term efficacy of acupoint application was superior to that of Western Medicine(at 3 months, 6 months and 1 year), oral Chinese medicine(at more than 6 months) and acupuncture(at 1 year). AA can reduce serum Ig E, EOS, and IL-4 level of AR patients in a short run. Acupoint application is safe, but severe skin reactions can reduce patient compliance.
